About this trial
Study aims to develop and to evaluate the neurophysiological and physiological response to a classical conditioning task.To better understand how Duchenne Muscular Dystrophy (DMD) and Becker Muscular Dystrophy (BMD) impacts mental health and how to assess it. Participants invited to complete questionnaires about behaviour, cognitive function and social interactions, complete computer tasks and have an optional MRI brain scan,
Eligibility criteria
Qualifiers
Male
Age range 7-17 years
A genetically proven diagnosis of DMD.
A genetic mutation that abrogates expression of Dp427 alone (assigned in DMD Group 1: Dp427-/Dp140+) or both Dp427 and Dp140 (assigned to DMD Group 2: Dp427-/Dp140-).
Disqualifiers
Significant visual or hearing impairment
Specific phobias or sensory sensitivities to stimuli similar to the ones used in this study
Current participation in a clinical trial investigating a new drug involved in dystrophin modulation.
Inability to consent (for parents/guardians or self-reporting participants aged 16 and 17) or assent. This will exclude the rare individuals with extremely severe learning disability, as the assent in these patients is impossible (or the consent in self-reporting participants aged 16 and 17).
Trial design
Treatments tested in this trial
- Classical conditioning task
Treatment groups
Sponsors and collaborators
University College, London
Lead sponsor
Sarepta Therapeutics, Inc.
Collaborator